Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06327945 · ClinicalTrials.gov registry record · NA
Transplanting Lungs From Uncontrolled Donation After Circulatory Death
A NA study of Lung Transplantation, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06327945: Recruiting NA study of Lung Transplantation, sponsored by NYU Langone Health.
NCT06327945 is a NA study of Lung Transplantation that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 24 participants, below the 334-participant average among 12 other Lung Transplantation trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06327945, a NA study of Lung Transplantation, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The study team developed an uncontrolled donation after circulatory death (uDCD) protocol that preserves lungs for just over 3 hours after death using positive end expiratory pressure (PEEP) and supplemental oxygen. The study will assess lung uDCD program safety by continuous review of operations/clinical records from each case activation and transplantation. Attrition outcomes include rates of initial and continued lung preservation, donation authorization, lung recovery, passing ex-vivo lung perfusion (EVLP) performance testing, and lung transplantation. Planned viability assessments also include macroscopic determination, radiology (X-ray), and fiber optic bronchoscopy before initiating EVLP. We expect \~50% of lungs assessed with EVLP will be transplanted to meet sustainability targets. Safety outcomes include the primary outcome, primary graft dysfunction (PGD) grade III at 72 hours, and secondarily survival one year after transplantation.
Primary Outcome
PGD is measured 72 hours after transplantation and defined according to the International Society for Heart and Lung Transplantation (ISHLT) criteria: partial pressure of arterial oxygen divided by the fraction of inspired oxygen (Pa02/FI02) \< 200 mm Hg.
Conditions Studied
Interventions
- DEVICE Lung uDCD Protocol
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-01-24 |
| Est. Completion | 2028-06-30 |
| Phase | NA |
What NCT06327945 shows while recruiting
NCT06327945 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 334-participant average among 12 other Lung Transplantation trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Lung Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Lung uDCD Protocol is the first listed.
NCT06327945 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06327945 about?
NCT06327945 is a clinical study titled "Transplanting Lungs From Uncontrolled Donation After Circulatory Death". The study team developed an uncontrolled donation after circulatory death (uDCD) protocol that preserves lungs for just over 3 hours after death using positive end expiratory pressure (PEEP) and supplemental oxygen. The study will assess lung uDCD program safety by continuous review of operations/cl...
What is the current status of trial NCT06327945?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2025-01-24. Estimated completion is 2028-06-30.
What conditions does trial NCT06327945 study?
This clinical trial studies the following conditions: Lung Transplantation.
What interventions are being tested in trial NCT06327945?
The interventions under investigation include: Lung uDCD Protocol (DEVICE).
Who is sponsoring clinical trial NCT06327945?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06327945 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06327945's enrollment target sits among peer trials
24 12th of 12 higher than 1 of 12 other Lung Transplantation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Inspiratory Muscle Training Immediately After Lung Transplantation
ACTIVE NOT RECRUITING · NA
-
Lung Transplant G0 (LTGO): Improving Self-Management of Exercise After Lung Transplantation
COMPLETED · NA
-
Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
RECRUITING
-
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
RECRUITING · Phase 2
-
Trifecta-Lung cfDNA-MMDx Study
RECRUITING
-
Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI